It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Protein-protein interactions (PPIs) stabilization with molecular glues plays a crucial role in drug discovery, albeit with significant challenges. In this study, we propose a dual-site approach, targeting the PPI region and its dynamic surroundings. We conduct molecular dynamics simulations to identify critical sites on the PPI that stabilize the cyclin-dependent kinase 12 - DNA damage-binding protein 1 (CDK12-DDB1) complex, resulting in further cyclin K degradation. This exploration leads to the creation of LL-K12-18, a dual-site molecular glue, which enhances the glue properties to augment degradation kinetics and efficiency. Notably, LL-K12-18 demonstrates strong inhibition of gene transcription and anti-proliferative effects in tumor cells, showing significant potency improvements in MDA-MB-231 (88-fold) and MDA-MB-468 cells (307-fold) when compared to its precursor compound SR-4835. These findings underscore the potential of dual-site approaches in disrupting CDK12 function and offer a structural insight-based framework for the design of cyclin K molecular glues.
Protein-protein interactions (PPIs) stabilization with molecular glues plays a crucial role in drug discovery. Here, the authors propose a dual-site approach for the design of clyclin K molecular glues, targeting the PPI region and its dynamic surroundings, and report a dual-site molecular glue for the cyclin-dependent kinase 12 - DNA damage-binding protein 1 complex, resulting in further cyclin K degradation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Fujian Medical University, The School of Pharmacy, Fuzhou, China (GRID:grid.256112.3) (ISNI:0000 0004 1797 9307)
2 Nanjing University of Chinese Medicine, School of Chinese Materia Medica, Nanjing, China (GRID:grid.410745.3) (ISNI:0000 0004 1765 1045); Chinese Academy of Sciences, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309)
3 Fujian Normal University, Key Laboratory of Microbial Pathogenesis and Interventions of Fujian Province University, the Key Laboratory of Innate Immune Biology of Fujian Province, Biomedical Research Center of South China, College of Life Sciences, Fuzhou, China (GRID:grid.411503.2) (ISNI:0000 0000 9271 2478)
4 Chinese Academy of Sciences, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309)
5 Chinese Academy of Sciences, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419)
6 Chinese Academy of Sciences, Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Zhongshan, China (GRID:grid.9227.e) (ISNI:0000000119573309)
7 University of Chinese Academy of Sciences, School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, Hangzhou, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419)
8 Nanjing University of Chinese Medicine, School of Chinese Materia Medica, Nanjing, China (GRID:grid.410745.3) (ISNI:0000 0004 1765 1045); Chinese Academy of Sciences, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309); University of Chinese Academy of Sciences, Beijing, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419)
9 Chinese Academy of Sciences, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309); Guizhou Medical University, State Key Laboratory of Functions and Applications of Medicinal Plants, School of Pharmacy, Guiyang, China (GRID:grid.413458.f) (ISNI:0000 0000 9330 9891)
10 Fujian Medical University, The School of Pharmacy, Fuzhou, China (GRID:grid.256112.3) (ISNI:0000 0004 1797 9307); Chinese Academy of Sciences, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309); Chinese Academy of Sciences, Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Zhongshan, China (GRID:grid.9227.e) (ISNI:0000000119573309); University of Chinese Academy of Sciences, School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, Hangzhou, China (GRID:grid.410726.6) (ISNI:0000 0004 1797 8419); Guizhou Medical University, State Key Laboratory of Functions and Applications of Medicinal Plants, School of Pharmacy, Guiyang, China (GRID:grid.413458.f) (ISNI:0000 0000 9330 9891)
11 Chinese Academy of Sciences, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309); Fujian Normal University, Key Laboratory of Microbial Pathogenesis and Interventions of Fujian Province University, the Key Laboratory of Innate Immune Biology of Fujian Province, Biomedical Research Center of South China, College of Life Sciences, Fuzhou, China (GRID:grid.411503.2) (ISNI:0000 0000 9271 2478); Chinese Academy of Sciences, Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Zhongshan, China (GRID:grid.9227.e) (ISNI:0000000119573309)